EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Randomised trial on treatment of vaginal high‐grade squamous intraepithelial lesion: Self‐administered vaginal imiquimod and laser vaporisation

Mari Kiviharju iD, Annika Riska, Ilkka Kalliala, Maija Jakobsson, Annu Heinonen, Joakim Dillner iD, Pekka Nieminen, Karoliina Aro iD

International Journal of Cancer · 2025-10 · 157 (7) · 1458-1464

DOI: 10.1002/ijc.35497 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, online erschienen am 02.06.2025. Verfasst von Mari Kiviharju und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Aminoquinolines, Laser Therapy, Vaginal Neoplasms, Squamous Intraepithelial Lesions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sigrid Juséliuksen Säätiö, Finnish Research Council, Suomen Lääketieteen Säätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High grade vaginal squamous intraepithelial lesion (HSIL) (or vaginal intraepithelial neoplasia; VAIN) is a rare human papillomavirus (HPV)‐related cancer precursor, which is commonly treated with laser vaporisation or other surgical methods to prevent progression to invasion. Vaginal HSIL has a substantial tendency to relapse despite treatment, for which HPV persistence is a known risk factor. Imiquimod is a topically applied immunomodulator and has shown promise in the treatment of high‐grade HPV‐related genital cancer precursors. The aim of this study was to assess the efficacy and patient compliance of self‐administered vaginal imiquimod in comparison to laser vaporisation in the treatment of vaginal HSIL. We recruited 56 women with histological vaginal HSIL into a randomised controlled trial of laser vaporisation and self‐administered vaginal imiquimod with follow‐up up to 6 months. Follow‐up visits included colposcopy, punch biopsies, and cervical or vaginal swabs for HPV genotyping. In per protocol analyses of 26 women in the laser arm and 27 women in the imiquimod arm, 53.8% and 77.8% ( p = 0.07), respectively, showed histological regression at the end of the study. No progressions to invasion were detected during the study period. Genotype‐specific post‐treatment negativity for HPV occurred in 16.7% of the laser group and in 39.1% of the imiquimod group ( p = 0.12). Imiquimod had short‐term adverse effects, but 93% completed treatment as instructed. We conclude that vaginal imiquimod is an effective treatment for vaginal HSIL and could be considered an alternative to laser vaporisation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminoquinolinesLaser TherapyVaginal NeoplasmsSquamous Intraepithelial LesionsAntineoplastic AgentsHumansFemaleImiquimodMiddle AgedAdultAdministration, IntravaginalPapillomavirus InfectionsSelf AdministrationTreatment Outcome

Stichwörter der Autor:innen

human papillomavirusimiquimodvaginal high grade squamous intraepithelial lesionvaginal intraepithelial neoplasia

Substanzen

ImiquimodAminoquinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.
  • Wellbeing Services County of Vantaa and Kerava, Vantaa, Finland.
  • Department of Metabolism, Digestion and Reproduction and Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College, London, UK.
  • Department of Obstetrics and Gynecology, Hyvinkää Hospital, Helsinki University Hospital and University of Helsinki, Hyvinkää, Finland.
  • Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.

ORCID-Profile: Mari Kiviharju, Joakim Dillner, Karoliina Aro

Förderung

  • Sigrid Juséliuksen Säätiö
  • Finnish Research Council
  • Suomen Lääketieteen Säätiö
  • HUS VTR

Zitieren

APA

Kiviharju, M., Riska, A., Kalliala, I., Jakobsson, M., Heinonen, A., Dillner, J., Nieminen, P., & Aro, K. (2025). Randomised trial on treatment of vaginal high‐grade squamous intraepithelial lesion: Self‐administered vaginal imiquimod and laser vaporisation. International Journal of Cancer, 157(7), 1458-1464. https://doi.org/10.1002/ijc.35497

Vancouver

Kiviharju M, Riska A, Kalliala I, Jakobsson M, Heinonen A, Dillner J, et al. Randomised trial on treatment of vaginal high‐grade squamous intraepithelial lesion: Self‐administered vaginal imiquimod and laser vaporisation. International Journal of Cancer. 2025;157(7):1458-1464. doi:10.1002/ijc.35497

BibTeX
@article{Kiviharju2025,
  author = {Kiviharju, Mari and Riska, Annika and Kalliala, Ilkka and Jakobsson, Maija and Heinonen, Annu and Dillner, Joakim and Nieminen, Pekka and Aro, Karoliina},
  title = {Randomised trial on treatment of vaginal high‐grade squamous intraepithelial lesion: Self‐administered vaginal imiquimod and laser vaporisation},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {157},
  number = {7},
  pages = {1458--1464},
  doi = {10.1002/ijc.35497}
}
Kostenlos starten →